DNA in situ hybridization (ISH) methods, particularly fluorescence in situ hybridization, have gained broad acceptance in the clinical cytogenetic and research communities, but are used less frequently by noncytogenetic diagnostic pathology services. This review discusses tumor-related ISH, including the advantages and limitations of enzymatic detection ("insituhistochemistry"). The ISH applications are categorized with respect to diagnostic capabilities, ease of use, and cost.